AbbVie reported strong Q2 earnings and revenue beats, but its stock declined due to a modest reduction in full-year adjusted EPS guidance. The guidance cut, primarily driven by the proposed acquisition of Apogee Therapeutics and R&D charges, overshadowed the positive quarterly performance, leading to a negative market reaction.
AbbVie's stock experienced a decline despite beating Q2 earnings and revenue estimates. The primary driver for this negative market reaction was a slight reduction in its full-year adjusted EPS guidance, which pushed the midpoint below analyst expectations. This guidance cut is attributed to the anticipated acquisition of Apogee Therapeutics and significant in-process R&D charges. While the acquisition is a long-term strategic move, its short-term impact on earnings guidance has soured investor sentiment, highlighting how sensitive the market is to future outlooks, even when current performance is strong. Traders should note the immediate negative reaction to the guidance, suggesting a focus on forward-looking statements over past performance.